Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells

Cancer Biology and Therapy

Volumn 13, Issue 2, 2012, Pages 71-76

  González, Jorge Ernesto ^a   Barquinero, Joan Francesc ^b   Lee, Manuel ^c   García, Omar ^a   Casacó, Angel ^d  

^a Laboratorio de Radiobiología   (Cuba)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Oficina Reguladora Ambiental Y Seguridad Nuclear   (Cuba)

^d CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

H2AX; A431 cells; Cetuximab; Epidermal growth factor receptors; Ionizing radiation; Nimotuzumab; Radiotherapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; NIMOTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; HUMAN; HUMAN CELL; IRRADIATION; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; COMBINED MODALITY THERAPY; DNA DAMAGE; HISTONES; HUMANS; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84863073998     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.2.18439     Document Type: Article

References (29)

1. Fortini P, Dogliotti E. Base damage and single-strand break repair: mechanisms and functional significance of shortand long-patch repair subpathways. DNA Repair (Amst) 2007; 6:398-409; PMID:17129767; http://dx.doi.org/10.1016/j.dnarep.2006.10.008
2. Caldecott KW. Mammalian single-strand break repair: mechanisms and links with chromatin. DNA Repair (Amst) 2007; 6:443-53; PMID:17118715; http://dx.doi.org/10.1016/j.dnarep.2006.10.006
3. Wyman C, Kanaar R. Homologous recombination: down to the wire. Curr Biol 2004; 14:R629-31; PMID: 15296782; http://dx.doi.org/10.1016/j.cub.2004.07.049
4. Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst) 2005; 4:639-48; PMID: 15907771; http://dx.doi.org/10.1016/j.dnarep.2004.12.005
5. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280:31182-9; PMID:16000298; http://dx.doi.org/10.1074/jbc.M506591200
6. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA dependent protein kinase in mammalian cells. J Biol Chem 1998; 273: 1568-73; PMID:9430697; http://dx.doi.org/10.1074/jbc.273.3.1568
7. Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 2004; 3:909-18; PMID:15279776; http://dx.doi.org/10.1016/j.dnarep.2004.03.021
8. Burma S, Chen BP, Chen DJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 2006; 5:1042-8; PMID:16822724; http://dx.doi.org/10.1016/j.dnarep.2006.05.026
9. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996; 1314:147-56; PMID:8972728; http://dx.doi.org/10.1016/S0167-4889(96)00068-7
10. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-6; PMID:12499279
11. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010; 12:675-84; PMID:20824044
12. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6:876-85; PMID:17036041; http://dx.doi.org/10.1038/nrc1953
13. Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009; 90:172-6; PMID:18976827; http://dx.doi.org/10.1016/j.radonc.2008.09.018
14. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody nimotuzumab in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54; PMID:15117987; http://dx.doi.org/10.1200/JCO.2004.03.089
15. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749-55; PMID: 18253126; http://dx.doi.org/10.1038/sj.bjc.6604222
16. Allan DGP. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005; 10:760-1; PMID: 16249358; http://dx.doi.org/10.1634/ theoncologist. 10-9-760
17. Dittmann K, Mayer C, Rodemann H-P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76:157-61; PMID:16024112; http://dx.doi.org/10.1016/j.radonc.2005.06.022
18. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11: 1-3; PMID:21189451; http://dx.doi.org/10.4161/cbt.11.4.14097
19. Puig P, Barquinero JF. An application of compound Poisson modeling to biological dosimetry. Proc R Soc A 2010; doi:10.1098/rspa.2010.0384.
20. Deckbar D, Birraux J, Krempler A, Tchouandong L, Beucher A, Walker S, et al. Chromosome breakage after G2 checkpoint release. J Cell Biol 2007; 176: 749-55; PMID:17353355; http://dx.doi.org/10.1083/jcb.200612047
21. Löbrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Natl Rev 2007; 7:861-9; PMID:17943134; http://dx.doi.org/10.1038/nrc2248
22. Redon CE, Nakamura AJ, Zhang Y-W, Ji J, Bonner WM, Kinders RJ, et al. Histone γH2AX and Poly (ADP-Ribose) as Clinical Pharmacodynamic Biomarkers. Clin Cancer Res 2010; 16:4532-42; PMID:20823146; http://dx.doi.org/10.1158/1078-0432.CCR-10-0523
23. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. γH2AX and cancer. Natl Rev 2008; 8:957-67; http://dx.doi.org/10.1038/ nrc2523
24. Banath JP, Peggy L. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63:4347-50. (Pubitemid 36951002)
25. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011; 11:247-56; PMID:21171927
26. Crombet T, Torres L, Neninger E, Catalá M, Solano M, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody nimotuzumab, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26:139-48; PMID:12616105; http://dx.doi.org/10.1097/00002371-200303000-00006
27. Fracasso P, Burris H, Arquette M, Govindan R, Gao F, Wright L, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13:986-93; PMID:17289894; http://dx.doi.org/10.1158/1078-0432.CCR-06-1542
28. Thomas P, Harvey S, Gruner T, Fenech M. The buccal cytome and micronucleus frequency is substantially altered in Down's syndrome and normal ageing compared to young healthy controls. Mutat Res 2008; 638:37-47; PMID:17920640; http://dx.doi.org/10.1016/j.mrfmmm.2007.08.012
29. González JE, Roch-Lefèvre SH, Mandina T, García O, Roy L. Induction of γ-H2AX foci in human exfoliated buccal cells after in vitro exposure to ionizing radiation. Int J Radiat Biol 2010; 86:752-9; PMID:20597838; http://dx.doi.org/10.3109/09553002.2010.484476